EMA Chided Over Lack of Transparency in Pediatric Trials Waiver Process
The EU Ombudsman June 4 criticized the European Medicines Agency’s (EMA) lack of transparency and guidelines for deciding when to require drugmakers to carry out pediatric clinical trials.